This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

59/100

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Plain-language summary

China has the largest population of patients with dementia in the world, imposing a heavy burden on the public and health care systems. More than 100 epidemiological studies on dementia have been done in China, but the estimates of the prevalence and incidence remain inconsistent because of the use of different sampling methods. Despite improved access to health services, inadequate diagnosis and management for dementia is still common, particularly in rural areas. The Chinese Government issued a new policy to increase care facilities for citizens older than 65 years, but most patients with dementia still receive care at home. Western medicines for dementia symptoms are widely used in China, but many patients choose Chinese medicines even though they have little evidence supporting efficacy. The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number. Efforts are needed to establish a national system of dementia care enhance training in dementia for health professionals, and develop global collaborations to prevent and cure this disease.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jia, L., Quan, M., Fu, Y., Zhao, T., Li, Y., Wei, C., et al. (2020). Dementia in China: epidemiology, clinical management, and research advances. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(19)30290-x

Vancouver

Jia L, Quan M, Fu Y, Zhao T, Li Y, Wei C, et al. Dementia in China: epidemiology, clinical management, and research advances. The Lancet. Neurology. 2020. doi:10.1016/s1474-4422(19)30290-x. PMID: 31494009.

BibTeX

@article{jia2020-31494009,
  author  = {Jia, L. and Quan, M. and Fu, Y. and Zhao, T. and Li, Y. and Wei, C. and Tang, Y. and Qin, Q. and others},
  title   = {{Dementia in China: epidemiology, clinical management, and research advances}},
  journal = {The Lancet. Neurology},
  year    = {2020},
  doi     = {10.1016/s1474-4422(19)30290-x},
  pmid    = {31494009},
  url     = {https://doi.org/10.1016/s1474-4422(19)30290-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

How to read this study

Design: this is a narrative review. It summarises a field without a fixed search method, so it shows how authors read the evidence rather than measuring it. Use it to find the primary studies, not as a result in itself.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

The number of clinical trials of Chinese and western medicines has substantially increased as a result of progress in research on new antidementia drugs but international multicentre studies are few in number.

Why it matters

This review describes the epidemiology, clinical management and research situation for dementia in China, noting that diagnosis and management remain inadequate in many areas and that evidence for Chinese medicines is limited. It calls for better care and more research but reports no treatment that cures or prevents Alzheimer's disease.

New to this subject? Start with our plain-English guide: Getting a diagnosis →

Study details

Evidence strengthLow

How this study scored 59/100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (The Lancet. Neurology)
Journal's citation record	3 / 4	The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	2 / 5	2020 — within 10 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	6 / 7	Cited 867 times (OpenAlex, 2026-10-10)
Citations per year	5 / 5	108.4 citations a year over 8 year(s) since 2020
Impact for its field and year	6 / 6	Cited 51.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	4 / 6	Cited by 33 other studies in this library
Still being cited	4 / 4	Cited 428 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	3 / 4	Last-listed author Jianping Jia: h-index 61 (OpenAlex, whole career)
Institution's track record	1 / 3	McGill University: institution h-index 1,373 (OpenAlex)
Multicenter collaboration	3 / 3	OpenAlex lists 21 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 31494009)
Free to read	0 / 2	Behind a paywall — scores zero
Total	59 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 30.

Later studies that cite this one

33 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis from nearby years

Also tagged “prevalence”

1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →